BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26323996)

  • 1. Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma.
    Ma Z; Liu W; Zeng J; Zhou J; Guo P; Xie H; Yang Z; Zheng L; Xu S; Wang X; Chang LS; He D; Li L
    Oncol Rep; 2015 Nov; 34(5):2461-8. PubMed ID: 26323996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autophagy induction by silibinin positively contributes to its anti-metastatic capacity via AMPK/mTOR pathway in renal cell carcinoma.
    Li F; Ma Z; Guan Z; Chen Y; Wu K; Guo P; Wang X; He D; Zeng J
    Int J Mol Sci; 2015 Apr; 16(4):8415-29. PubMed ID: 25884331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel.
    Chang HR; Chen PN; Yang SF; Sun YS; Wu SW; Hung TW; Lian JD; Chu SC; Hsieh YS
    Mol Carcinog; 2011 Oct; 50(10):811-23. PubMed ID: 21574189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway.
    Liang L; Li L; Zeng J; Gao Y; Chen YL; Wang ZQ; Wang XY; Chang LS; He D
    Oncol Rep; 2012 Sep; 28(3):999-1005. PubMed ID: 22736024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.
    D'Amato C; Rosa R; Marciano R; D'Amato V; Formisano L; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fulciniti F; Cipolletta A; Bianco C; Ciardiello F; Veneziani BM; De Placido S; Bianco R
    Br J Cancer; 2014 Sep; 111(6):1168-79. PubMed ID: 25093491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN.
    Deng W; Han W; Fan T; Wang X; Cheng Z; Wan B; Chen J
    Biomed Pharmacother; 2018 Nov; 107():1505-1513. PubMed ID: 30257368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.
    Wu M; Si S; Li Y; Schoen S; Xiao GQ; Li X; Teh BT; Wu G; Chen J
    Oncotarget; 2015 Oct; 6(32):32761-73. PubMed ID: 26418749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-canonical GLI1/2 activation by PI3K/AKT signaling in renal cell carcinoma: A novel potential therapeutic target.
    Zhou J; Zhu G; Huang J; Li L; Du Y; Gao Y; Wu D; Wang X; Hsieh JT; He D; Wu K
    Cancer Lett; 2016 Jan; 370(2):313-23. PubMed ID: 26577809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft.
    Ubai T; Azuma H; Kotake Y; Inamoto T; Takahara K; Ito Y; Kiyama S; Sakamoto T; Horie S; Muto S; Takahara S; Otsuki Y; Katsuoka Y
    Anticancer Res; 2007; 27(1A):75-88. PubMed ID: 17352219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.
    Xiong Z; Zang Y; Zhong S; Zou L; Wu Y; Liu S; Fang Z; Shen Z; Ding Q; Chen S
    Oncotarget; 2017 May; 8(18):30151-30161. PubMed ID: 28404914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
    Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
    Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
    Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
    BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silibinin inhibits epithelial‑mesenchymal transition of renal cell carcinoma through autophagy‑dependent Wnt/β‑catenin signaling.
    Fan Y; Hou T; Dan W; Liu T; Luan J; Liu B; Li L; Zeng J
    Int J Mol Med; 2020 May; 45(5):1341-1350. PubMed ID: 32323735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
    Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
    Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oridonin inhibits mTOR signaling and the growth of lung cancer tumors.
    Wang YY; Lv YF; Lu L; Cai L
    Anticancer Drugs; 2014 Nov; 25(10):1192-200. PubMed ID: 25075795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
    He M; Fu Y; Yan Y; Xiao Q; Wu H; Yao W; Zhao H; Zhao L; Jiang Q; Yu Z; Jin F; Mi X; Wang E; Cui Z; Fu L; Chen J; Wei M
    Clin Sci (Lond); 2015 Nov; 129(9):809-22. PubMed ID: 26201092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLI1 overexpression promotes gastric cancer cell proliferation and migration and induces drug resistance by combining with the AKT-mTOR pathway.
    Yao Y; Zhou D; Shi D; Zhang H; Zhan S; Shao X; Sun K; Sun L; Wu G; Tian K; Zhu X; He S
    Biomed Pharmacother; 2019 Mar; 111():993-1004. PubMed ID: 30841479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abrogation of STAT3 signaling cascade by zerumbone inhibits proliferation and induces apoptosis in renal cell carcinoma xenograft mouse model.
    Shanmugam MK; Rajendran P; Li F; Kim C; Sikka S; Siveen KS; Kumar AP; Ahn KS; Sethi G
    Mol Carcinog; 2015 Oct; 54(10):971-85. PubMed ID: 24797723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silibinin suppresses the maintenance of colorectal cancer stem-like cells by inhibiting PP2A/AKT/mTOR pathways.
    Wang JY; Chang CC; Chiang CC; Chen WM; Hung SC
    J Cell Biochem; 2012 May; 113(5):1733-43. PubMed ID: 22213051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silibinin inhibits tumor growth through downregulation of extracellular signal-regulated kinase and Akt in vitro and in vivo in human ovarian cancer cells.
    Cho HJ; Suh DS; Moon SH; Song YJ; Yoon MS; Park DY; Choi KU; Kim YK; Kim KH
    J Agric Food Chem; 2013 May; 61(17):4089-96. PubMed ID: 23570653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.